[HTML][HTML] LAG-3: from molecular functions to clinical applications
T Maruhashi, D Sugiura, I Okazaki… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
To prevent the destruction of tissues owing to excessive and/or inappropriate immune
responses, immune cells are under strict check by various regulatory mechanisms at …
responses, immune cells are under strict check by various regulatory mechanisms at …
LAG 3 (CD 223) as a cancer immunotherapy target
LP Andrews, AE Marciscano, CG Drake… - Immunological …, 2017 - Wiley Online Library
Despite the impressive impact of CTLA 4 and PD 1‐PDL 1‐targeted cancer immunotherapy,
a large proportion of patients with many tumor types fail to respond. Consequently, the focus …
a large proportion of patients with many tumor types fail to respond. Consequently, the focus …
Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor
Immune checkpoint therapy has revolutionized cancer treatment by blocking inhibitory
pathways in T cells that limits the an effective anti-tumor immune response. Therapeutics …
pathways in T cells that limits the an effective anti-tumor immune response. Therapeutics …
Immune checkpoint LAG3 and its ligand FGL1 in cancer
AP Shi, XY Tang, YL Xiong, KF Zheng, YJ Liu… - Frontiers in …, 2022 - frontiersin.org
LAG3 is the most promising immune checkpoint next to PD-1 and CTLA-4. High LAG3 and
FGL1 expression boosts tumor growth by inhibiting the immune microenvironment. This …
FGL1 expression boosts tumor growth by inhibiting the immune microenvironment. This …
Counteracting CAR T cell dysfunction
In spite of high rates of complete remission following chimeric antigen receptor (CAR) T cell
therapy, the efficacy of this approach is limited by generation of dysfunctional CAR T cells in …
therapy, the efficacy of this approach is limited by generation of dysfunctional CAR T cells in …
The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: third time'sa charm
Q Lecocq, M Keyaerts, N Devoogdt… - International journal of …, 2020 - mdpi.com
The blockade of immune checkpoints (ICPs), such as cytotoxic T lymphocyte associated
protein-4 (CTLA-4) and programmed death-1 (PD-1) and its ligand (PD-L1), has propelled …
protein-4 (CTLA-4) and programmed death-1 (PD-1) and its ligand (PD-L1), has propelled …
[HTML][HTML] LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
RY Huang, C Eppolito, S Lele, P Shrikant, J Matsuzaki… - Oncotarget, 2015 - ncbi.nlm.nih.gov
The immune co-inhibitory receptors lymphocyte activation gene-3 (LAG3) and programmed
cell death 1 (PD1) synergistically contribute to autoimmunity and tumor evasion. Here we …
cell death 1 (PD1) synergistically contribute to autoimmunity and tumor evasion. Here we …
Cutting-edge: Preclinical and clinical development of the first approved lag-3 inhibitor
L Chocarro, A Bocanegra, E Blanco… - Cells, 2022 - mdpi.com
Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since
the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 …
the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 …
Understanding LAG-3 signaling
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple
biological activities over T cell activation and effector functions. LAG-3 plays a regulatory …
biological activities over T cell activation and effector functions. LAG-3 plays a regulatory …
Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators
I Le Mercier, JL Lines, RJ Noelle - Frontiers in immunology, 2015 - frontiersin.org
In the last two years, clinical trials with blocking antibodies to the negative checkpoint
regulators CTLA-4 and PD-1 have rekindled the hope for cancer immunotherapy. Multiple …
regulators CTLA-4 and PD-1 have rekindled the hope for cancer immunotherapy. Multiple …